Accelerate your DBTL cycle with the world’s fastest-growing microbial chassis. CD Biosynsis offers a comprehensive suite of genetic engineering services for Vibrio natriegens. By integrating industry-leading technologies such as CRISPR-Cas9, Lambda-Red recombineering, and high-throughput natural transformation platforms, we provide high-efficiency, scarless genomic modifications. Our platform is designed to reduce strain construction timelines from months to mere weeks, helping you harness the power of this sub-10-minute doubling-time organism.
Get a Technical QuoteOur V. natriegens engineering platform provides precise, marker-free modifications across both chromosomes. We specialize in overcoming unique challenges such as dual-chromosome stability and high metabolic flux redirection.
| Service Tier | Technical Strategy | Best For | Standard Deliverables |
|---|---|---|---|
| Standard Knockout | CRISPR-Cas9 / Lambda-Red | Functional genomics & single-gene disruption | 2 Validated stocks + Sanger Report |
| Multiplex Transformation | Natural Transformation Platform | Pathway optimization (3-9 edits simultaneously) | Mutant library or selected high-titer strains |
| Pathway Integration | KIKO (Knock-in/Knock-out) | Stable heterologous expression | Integrated strain + Expression QC |
| Chassis Streamlining | Sequential Deletion | Minimal genome construction | Marker-free chassis + WGS |
1. Consultation & Design
2. Vector Construction
3. Transformation & Editing
4. Validation & Delivery
Sequence analysis and bioinformatic design of sgRNAs or homology arms.
Formal project proposal and Mutual NDA signing.
Assembly of CRISPR vectors or natural transformation donor fragments.
Codon optimization for heterologous genes.
Optimized delivery into V. natriegens.
Precise editing and curing of editing plasmids.
Validation via Junction PCR and Sanger sequencing.
Full QC report delivery (Optional NGS/WGS).
To provide the highest level of service, our team continuously benchmarks our internal protocols against landmark studies in the field of Vibrio engineering.
Academic research has demonstrated that utilizing Lambda-Red homologs (specifically SXT-Beta/Exo) can increase allelic exchange in V. natriegens by ~10,000-fold. CD Biosynsis applies these high-efficiency recombineering principles to ensure successful genomic deletions even in "hard-to-reach" loci.
(Reference: Lee et al., Harvard Medical School)
In multiplex scenarios, technologies like Multiplex Genome Editing by Natural Transformation allow for the simultaneous editing of up to 9 genes. This approach was famously used to enhance Poly-beta-hydroxybutyrate (PHB) production by 100-fold within a single week. We offer this high-throughput capability for customers looking to optimize complex pathways.
(Reference: Dalia et al., ACS Synth. Biol.)
Engineering V. natriegens for organic acid production requires a strategic "knockout cocktail." By benchmarking against successful Delta ldhA, Delta pfl, Delta ald strategies, we help clients achieve yields as high as 85% of the theoretical maximum.
(Reference: Thoma et al., Microbial Biotech.)
Reliable engineering depends on standardized parts. Our service integrates the logic of the Vnat Collection—a modular toolkit for Golden Gate assembly—ensuring that gene expression remains predictable and stable across both chromosomes.
(Reference: Faber et al., Nucleic Acids Research)
1. How long does a single gene knockout take?
Our standard turnaround time from design to validated strain is 4–6 weeks.
2. Is it possible to delete multiple genes at once?
Yes. Using our high-throughput natural transformation platform, we can target 3 to 5+ genes simultaneously.
3. Do you provide validation data?
Every project includes a QC report with Junction PCR and bi-directional Sanger sequencing data.
4. How do you ensure the stability of the dual-chromosome system?
Our targeting strategies ensure that deletions are fixed across all chromosome copies, preventing genotype reversion.
5. What about IP and confidentiality?
All projects are under a Mutual NDA. Engineered strains are 100% owned by the client.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.